Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)

Pinar Kanlikilicer, Recep Bayraktar, Merve Denizli, Mohammed H. Rashed, Cristina Ivan, Burcu Aslan, Rahul Mitra, Kubra Karagoz, Emine Bayraktar, Xinna Zhang, Cristian Rodriguez-Aguayo, Amr Ahmed El-Arabey, Nermin Kahraman, Seyda Baydogan, Ozgur Ozkayar, Michael L. Gatza, Bulent Ozpolat, George A. Calin, Anil K. Sood, Gabriel Lopez-Berestein

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

The authors would like to point out that the affiliations of the author Amr Ahmed El-Arabey should be: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA and Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.

Original languageEnglish (US)
Article number102630
JournalEBioMedicine
Volume52
DOIs
StatePublished - Feb 2020

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112](S2352396418304973)(10.1016/j.ebiom.2018.11.004)'. Together they form a unique fingerprint.

Cite this